Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Eli Lilly (exclusive license to develop, manufacture and commercialize tibulizumab, Apr 2023; up to $155M development milestones + $440M sales milestones)
Indications
hidradenitis suppurativa (HS)(Phase 2)
systemic sclerosis (SSc), early diffuse cutaneous(Phase 2)
polymyalgia rheumatica (PMR)(Phase 2)
Catalysts
— Q4 2026
— end of 2026
— H1 2027
Status note Lead candidate; bispecific dual-antagonist antibody (tabalumab fused with scFv from ixekizumab). TibuSHIELD (HS) and TibuSURE (SSc) are global randomized double-blind placebo-controlled Phase 2 trials.
crebankitug
Phase 1 · ActiveModality: antibody
Target IL-7Rα
Status note Evaluated in Phase 1 and Phase 1b studies; company assessing potential therapeutic indications and future development strategies.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.